Amy Zhou
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amy Zhou as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04543279 · Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaWashington University School of Medicine · terminated · Myelofibrosis, Thrombocytopenia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:31 UTC. The ranking covers the 200 most relevant of 120 PubMed records, and a shared surname and initials can bring in a namesake. All 120 on PubMed
- Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).J Clin Oncol · 2022435 citationsRCR 35.8
- Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.Clin Cancer Res · 2021256 citationsRCR 14.2
- Health Care Hotspotting - A Randomized, Controlled Trial.N Engl J Med · 2020253 citationsRCR 16.9
- 176 citationsRCR 7.7
- 175 citationsRCR 21.7
- Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.J Immunother Cancer · 2020142 citationsRCR 5.3
- Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.J Hematol Oncol · 2021133 citationsRCR 6.3
- 130 citationsRCR 6.4
- Why Did I Stop? Barriers and Facilitators to Uptake and Adherence to ART in Option B+ HIV Care in Lilongwe, Malawi.PLoS One · 2016104 citationsRCR 6.1
- 103 citationsRCR 4.2